Profile data is unavailable for this security.
About the company
Glenmark Life Sciences Limited is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as anti-fungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of approximately 1198 KL.
- Revenue in INR (TTM)22.05bn
- Net income in INR4.24bn
- Incorporated2011
- Employees2.01k
- LocationGlenmark Life Sciences LtdGlenmark HouseB. D. Sawant Marg, Andheri (East)MUMBAI 400099IndiaIND
- Phone+91 2 268297979
- Websitehttps://www.glenmarklifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orchid Pharma Ltd | 8.81bn | 1.12bn | 73.94bn | 872.00 | 63.70 | -- | 50.46 | 8.39 | 22.89 | 22.89 | 180.65 | -- | -- | -- | -- | 10,101,540.00 | -- | -0.9734 | -- | -1.40 | 40.67 | 40.74 | 12.78 | -2.40 | -- | 6.08 | -- | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| Blue Jet Healthcare Ltd | 6.95bn | 1.57bn | 82.01bn | 447.00 | 52.09 | -- | 44.83 | 11.80 | 9.08 | 9.08 | 40.07 | -- | -- | -- | -- | 15,547,110.00 | -- | -- | -- | -- | 55.54 | -- | 22.65 | -- | -- | 124.37 | -- | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Shilpa Medicare Ltd | 11.84bn | 447.57m | 82.55bn | 931.00 | 169.00 | -- | 53.93 | 6.97 | 5.00 | 5.00 | 133.55 | -- | -- | -- | -- | 12,716,850.00 | -- | 2.84 | -- | 3.65 | 65.19 | 60.08 | 3.79 | 7.03 | -- | 1.56 | -- | 10.76 | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Procter & Gamble Health Ltd | 11.51bn | 2.01bn | 86.85bn | 1.41k | 43.24 | 16.14 | 38.03 | 7.54 | 121.01 | 121.01 | 693.20 | 324.24 | 1.21 | 2.71 | 11.45 | -- | 21.21 | -- | 29.28 | -- | 71.29 | -- | 17.46 | -- | 1.90 | 386.94 | 0.0175 | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| F D C Ltd | 20.45bn | 3.14bn | 88.98bn | 6.66k | 28.45 | -- | 25.02 | 4.35 | 19.21 | 19.21 | 124.56 | -- | -- | -- | -- | 3,070,786.00 | -- | 12.05 | -- | 13.73 | 65.55 | 61.54 | 15.37 | 15.85 | -- | 75.15 | -- | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Sanofi Consumer Healthcare India Ltd | 8.01bn | 2.31bn | 113.42bn | -- | 49.16 | 61.44 | 48.41 | 14.16 | 100.17 | 100.17 | 347.67 | 80.15 | -- | -- | -- | -- | -- | -- | -- | -- | 71.64 | -- | 28.81 | -- | 2.27 | 3,260.00 | 0.0986 | -- | -- | -- | -- | -- | -- | -- |
| Glenmark Life Sciences Ltd | 22.05bn | 4.24bn | 129.54bn | 2.01k | 30.67 | 5.10 | 26.95 | 5.88 | 34.47 | 34.47 | 179.44 | 207.17 | 0.7304 | 1.46 | 2.79 | 10,947,850.00 | 14.03 | 18.28 | 16.69 | 29.99 | 54.92 | 53.40 | 19.21 | 20.23 | 3.03 | 380.55 | 0.0063 | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Marksans Pharma Ltd | 22.68bn | 3.34bn | 131.26bn | 2.00k | 39.29 | -- | 31.66 | 5.79 | 7.37 | 7.37 | 50.09 | -- | -- | -- | -- | 11,339,960.00 | -- | 14.62 | -- | 18.52 | 53.39 | 50.52 | 14.71 | 14.03 | -- | 32.19 | -- | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Akums Drugs and Pharmaceuticals Ltd | -100.00bn | -100.00bn | 132.51bn | 7.39k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| Granules India Ltd | 47.01bn | 4.92bn | 138.05bn | 4.12k | 28.07 | -- | 19.64 | 2.94 | 20.29 | 20.29 | 193.87 | -- | -- | -- | -- | 11,403,970.00 | -- | 10.68 | -- | 16.18 | 56.89 | 48.83 | 10.47 | 11.82 | -- | 6.95 | -- | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Strides Pharma Science Ltd | 44.10bn | 1.77bn | 143.04bn | 3.07k | 80.93 | 6.29 | 38.48 | 3.24 | 19.22 | 25.15 | 479.84 | 247.16 | 0.7155 | 1.50 | 3.57 | 14,389,290.00 | 2.79 | -1.68 | 5.43 | -2.97 | 60.19 | 51.39 | 3.91 | -3.36 | 0.6355 | 1.52 | 0.5103 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Caplin Point Laboratories Ltd | 17.58bn | 4.78bn | 154.71bn | 859.00 | 32.48 | -- | 28.64 | 8.80 | 62.67 | 62.67 | 230.62 | -- | -- | -- | -- | 20,462,630.00 | -- | 19.83 | -- | 22.82 | 58.41 | 53.38 | 27.43 | 25.39 | -- | 1,525.59 | -- | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| Sanofi India Ltd | 23.83bn | 4.30bn | 156.48bn | 2.17k | 36.41 | 22.86 | 33.44 | 6.57 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Eris Lifesciences Ltd | 24.98bn | 3.48bn | 180.09bn | 3.08k | 51.74 | 6.49 | 28.91 | 7.21 | 25.57 | 25.57 | 183.35 | 203.74 | 0.4585 | 2.90 | 5.96 | 8,110,753.00 | 6.73 | 13.42 | 8.39 | 16.80 | 77.03 | 79.98 | 14.69 | 24.96 | 0.8599 | 3.41 | 0.4626 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Wockhardt Ltd | 28.93bn | -3.43bn | 185.39bn | 2.39k | -- | -- | -- | 6.41 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 187.40bn | 1.65k | 55.76 | -- | 47.03 | 11.46 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
Data as of Nov 01 2024. Currency figures normalised to Glenmark Life Sciences Ltd's reporting currency: Indian Rupee INR
8.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Polar Capital LLPas of 30 Aug 2024 | 3.42m | 2.79% |
| MIT Investment Management Co.as of 30 Jun 2024 | 1.75m | 1.43% |
| quant Money Managers Ltd.as of 30 Sep 2024 | 1.60m | 1.31% |
| Union Asset Management Co. Pvt Ltd.as of 30 Sep 2024 | 889.54k | 0.73% |
| Jupiter Asset Management Ltd.as of 30 Jun 2024 | 601.43k | 0.49% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 2024 | 563.94k | 0.46% |
| HSBC Global Asset Management (Hong Kong) Ltd.as of 30 Sep 2021 | 541.99k | 0.44% |
| Mellon Investments Corp.as of 03 Oct 2024 | 182.98k | 0.15% |
| Old Bridge Asset Management Pvt Ltd.as of 30 Sep 2024 | 168.75k | 0.14% |
| JM Financial Asset Management Ltd.as of 30 Sep 2024 | 158.08k | 0.13% |
More ▼
Data from 30 Jun 2024 - 15 Oct 2024Source: FactSet Research Systems Inc.
